Rapamycin enhances the anti-tumor activity of cabozantinib in cMet inhibitor-resistant hepatocellular carcinoma
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers of Medicine"
DOI: 10.1007/s11684-021-0869-y
Abstract: Cabozantinib, mainly targeting cMet and vascular endothelial growth factor receptor 2, is the second-line treatment for patients with advanced hepatocellular carcinoma (HCC). However, the lower response rate and resistance limit its enduring clinical benefit. In… read more here.
Keywords: hepatocellular carcinoma; cmet inhibitor; rapamycin; cmet ... See more keywords
Inflammatory signaling pathways play a role in SYK inhibitor resistant AML
Sign Up to like & getrecommendations! Published in 2025 at "Scientific Reports"
DOI: 10.1038/s41598-025-96660-w
Abstract: Trials have shown promising clinical activity of the selective SYK inhibitor entospletinib in patients with high expressing HOXA9/MEIS1 acute leukemias. As the development of resistance mechanisms is a common problem in the use of targeted… read more here.
Keywords: inflammatory signaling; signaling pathways; inhibitor; resistant aml ... See more keywords
Abstract P3-01-16: Evaluation of the Combination of Vepdegestrant, a PROTAC Estrogen Receptor (ER) Degrader, Plus Palbociclib in CDK4/6 Inhibitor-Resistant WT ER and ER Y537S Mutant Patient-Derived Xenograft (PDX) Models
Sign Up to like & getrecommendations! Published in 2025 at "Clinical Cancer Research"
DOI: 10.1158/1557-3265.sabcs24-p3-01-16
Abstract: Background: Vepdegestrant is an oral PROteolysis TArgeting Chimera (PROTAC) ER degrader that directly ubiquitinates and degrades wild-type ER and clinically relevant mutants. Vepdegestrant demonstrated superior ER degradation and antitumor activity compared with the selective ER… read more here.
Keywords: cdk4 inhibitor; combination; pbr; inhibitor resistant ... See more keywords